Arena Pharmaceuticals, Inc. (ARNA)

1 member of Congress has disclosed 3 trades in Arena Pharmaceuticals, Inc. (ARNA) via STOCK Act filings. The most recent disclosure was a purchase by John A. Yarmuth on 12 February 2021. Aggregate disclosed activity totals roughly $24K in purchases (midpoint estimates from bracketed disclosure amounts).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Price data is not available for ARNA
This ticker may have been delisted, renamed, or is not publicly quoted, so no live price, statistics or chart can be shown. The congressional trades disclosed for it are listed below.

Congressional Trading Activity for ARNA

3 transactions
Compliance: 67%
John A. Yarmuth12 Feb 202119 Feb 2021PurchaseStock$1,001 - $15,000N/A
John A. Yarmuth12 Feb 202128 Jul 2022PurchaseStock$1,001 - $15,000N/A
John A. Yarmuth5 Nov 202015 Nov 2020PurchaseStock$1,001 - $15,000N/A

Stock Overview

Market Data

Market Cap

$0

Volume

0

Beta

0.55

P/E Ratio

-9.86

Fundamentals

EPS

$-10.14

Div. Yield

-

Open

$99.97

Day Range

$99.97 – $100.00

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Amit Munshi
IPO Date
2000-07-28
Website
www.arenapharm.com

Arena Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing innovative therapeutic agents, specifically designed with distinct pharmacological and pharmacokinetic profiles, for a global patient population. Its extensive pipeline f...

Earnings

Recent Quarters

Q1 20224 May
EPS-
Q4 202123 Feb
EPS$-2.39
Miss 5.8%
Q3 20214 Nov
EPS$-3.21
Miss 26.9%
Q2 20215 Aug
EPS$-2.40
Miss 9.1%
Q1 20215 May
EPS$-1.98
Beat 8.3%
Q4 202023 Feb
EPS$-2.10
Miss 13.5%
Q3 20209 Nov
EPS$-1.69
Beat 9.6%
Q2 20205 Aug
EPS$-1.61
Beat 20.7%
Q1 20207 May
EPS$-2.00
Beat 12.3%
Q4 201926 Feb
EPS$-1.76
Miss 13.6%
Q3 20197 Nov
EPS$-1.46
Miss 10.6%
Q2 20197 Aug
EPS$-1.24
Miss 14.8%
Q1 20198 May
EPS$12.10
Miss 12.9%
Q4 201826 Feb
EPS$1.35
Beat 277.6%
Q3 20187 Nov
EPS$-0.70
Beat 5.4%
Q2 20186 Aug
EPS$-0.65
Miss 1.6%
Q1 20188 May
EPS$-0.80
Miss 17.6%
Q4 201714 Mar
EPS$-0.35
Beat 40.7%
Q3 20177 Nov
EPS$-0.86
Miss 28.4%
Q2 20177 Aug
EPS$-0.77
Miss 4.0%
Q1 20179 May
EPS$-0.90
Miss 25.0%
Q4 201614 Mar
EPS$1.60
Beat 310.5%
Q3 20167 Nov
EPS$-0.50
Beat 24.2%
Q2 20168 Aug
EPS$-1.10
Miss 13.4%
Q1 20169 May
EPS$-0.90
Beat 12.6%
Q4 201529 Feb
EPS$-1.10
Beat 15.4%
Q3 20159 Nov
EPS$-1.10
Beat 17.9%
Q2 20155 Aug
EPS$-1.10
Beat 20.9%
Q1 201511 May
EPS$-0.10
Beat 28.6%
Q4 20142 Mar
EPS$-0.15
Miss 25.0%
Q3 20143 Nov
EPS$-0.05
Beat 54.5%
Q2 20141 Aug
EPS$-1.20
Miss 13.2%
Q1 201412 May
EPS$-1.20
Miss 15.4%
Q4 201327 Feb
EPS$-1.10
Miss 558.3%
Q3 20137 Nov
EPS$-0.80
Beat 31.0%
Q2 20131 Aug
EPS$1.80
Beat 17.6%
Q1 20132 May
EPS$-0.90
Miss 204.7%
Q4 20124 Mar
EPS$-1.00
Miss 257.1%
Q3 20126 Nov
EPS$-0.70
Beat 18.6%
Q2 20129 Aug
EPS$-1.20
Miss 79.1%
Q1 20121 May
EPS$-1.80
Miss 44.0%
Q4 201114 Mar
EPS$-1.60
Miss 7.4%
Q3 20119 Nov
EPS$-1.60
Miss 16.8%
Q2 20119 Aug
EPS$-1.60
Miss 2.6%
Q1 201110 May
EPS$-3.50
Miss 65.9%
Q3 201031 Dec
EPS$-2.32
Q3 20109 Nov
EPS$-3.10
Miss 36.6%
Q2 20103 Aug
EPS$-2.80
Beat 2.4%
Q1 20107 May
EPS$-3.30
Miss 4.4%
Q4 200912 Mar
EPS$-3.20
Miss 4.6%
Q3 20099 Nov
EPS$-3.80
Miss 12.4%
Q2 20093 Aug
EPS$-4.80
Beat 1.0%
Q1 200911 May
EPS$-6.80
Beat 0.3%
Q4 200812 Mar
EPS$-8.40
Miss 7.3%
Q3 200830 Oct
EPS$-7.60
Beat 8.7%
Q2 20085 Aug
EPS$-8.90
Miss 20.1%
Q1 20087 May
EPS$-7.50
Miss 11.3%
Q4 200727 Feb
EPS$-6.00
Beat 23.5%
Q3 200717 Oct
EPS$-5.40
Beat 23.9%
Q2 200719 Jul
EPS$-6.40
Beat 0.2%
Q1 200718 Apr
EPS$-5.30
Beat 20.9%
Q4 200621 Feb
EPS$-7.60
Beat 16.7%
Q3 200625 Oct
EPS$-4.30
Beat 28.3%
Q2 200625 Jul
EPS$-4.00
Beat 8.1%
Q1 20068 May
EPS$-3.00
Beat 27.9%
Q4 200522 Feb
EPS$-5.50
Beat 0.9%
Q3 200517 Oct
EPS$-4.60
Beat 5.9%
Q2 200519 Jul
EPS$-4.60
Beat 4.6%
Q1 200526 Apr
EPS$-7.90
Miss 32.8%
Q4 200416 Feb
EPS$-7.00
Miss 12.4%
Q3 200420 Oct
EPS$-5.40
Beat 11.5%
Q2 200420 Jul
EPS$-6.70
Miss 21.8%
Q1 200420 Apr
EPS$-4.90
Miss 16.7%
Q3 200331 Dec
EPS$-5.78
Q2 200330 Sept
EPS$-4.28
Q1 200330 Jun
EPS$-4.24
Q4 200231 Mar
EPS$-3.19
Q4 200220 Jan
EPS$-3.20
Beat 28.9%
Q3 200229 Oct
EPS$-3.70
Miss 13.2%
Q2 200223 Jul
EPS$-2.70
Miss 9.8%
Q1 200224 Apr
EPS$-2.40
Miss 41.2%
Q4 200117 Jan
EPS$-1.00
Miss 5.3%
Q3 200118 Oct
EPS$-0.70
Miss 18.6%
Q2 200123 Jul
EPS$-1.40
Miss 683.3%
Q1 200117 Apr
EPS$0.50
Beat 11.1%
Q4 200018 Jan
EPS$0.50
Miss 23.1%
Q3 200025 Oct
EPS$-0.70
Beat 38.0%
Q1 200030 Jun
EPS$-2.94
Q4 199931 Mar
EPS$-3.18

1 politician traded within 30 days

No dividend data available for this stock.

Stock Splits

Split History

19 Jun 2017Reverse Split
Ratio1:10

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about ARNA

Which members of Congress have traded ARNA?
1 member of Congress has disclosed 3 trade in Arena Pharmaceuticals, Inc. (ARNA) under the STOCK Act: John A. Yarmuth.
When was ARNA most recently disclosed by Congress?
The most recent ARNA disclosure was a purchase by John A. Yarmuth on 12 February 2021.
What is the total disclosed congressional trading volume for ARNA?
Members of Congress have disclosed approximately $24K in ARNA purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in ARNA?
This ARNA page updates as soon as new STOCK Act disclosures are filed for Arena Pharmaceuticals, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.